33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: Results from istopmm, a population-based screening study in Iceland
    Meeting Abstract

    Rögnvaldsson, S.; Gasparini, A.; Thorsteinsdottir, S.; Sverrisdottir, I.; Eythorsson, E.; Long, T. E.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B.; Sigurdardottir, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Effects of idecabtagene vicleucel (ide-cel) versus standard regimens on health-related quality of life (HRQoL) in patients with triple-class-exposed (TCE) relapsed/refractory multiple myeloma (RRMM) who received at least 3 lines of prior antimyeloma regimens in the KarMMa-3 phase 3 randomized controlled trial
    Meeting Abstract

    Delforge, M.; Patel, K. K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A randomized phase 2 trial of 28-day (Arm A) versus 14-Day (Arm B) schedule of venetoclax plus azacitidine in newly diagnosed acute myeloid leukemia patients ≥ 60 years
    Meeting Abstract

    Borate, U. M.; Huang, Y.; Johnson, M. F.; Zeidner, J. F.; Swords, R. T.; Koenig, K. L.; Stein, E. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Plasma circulating tumor DNA (ctDNA) as an alternative to tissue DNA for genotyping of DLBCL: Results from the POLARIX study
    Meeting Abstract

    Jardin, F.; Raghavan, V.; Tracy, S.; Balasubramanian, S.; Sehn, L. H.; Flowers, C. R.; Morschhauser, F.; Herrera, A. F.; Trněný, M.; Sharman, J. P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clonal hematopoiesis is common in unrelated stem cell donors but has no impact on patient outcome after hematopoietic stem cell transplantation
    Meeting Abstract

    Schetelig, J.; Damm, F.; Günther, U. P.; Baldauf, H.; Rave, C.; Koster, L.; Schöfl, G.; Klussmeier, A.; Menghrajani, K.; Bolton, K. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Genetic determinants of clonal hematopoiesis and progression to hematologic malignancies in 479,117 individuals
    Meeting Abstract

    Liu, J.; Tran, D.; Chan, I. C. C.; Wiley, B.; Watson, C.; Batchi-Bouyou, A. L.; Zong, X.; Stopsack, K. H.; Pharoah, P.; Ding, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Itacitinib for the prevention of immune effector cell therapy-associated cytokine release syndrome: Results from the phase 2 INCB 39110-211 placebo-controlled randomized cohort
    Meeting Abstract

    Frigault, M. J.; Maziarz, R. T.; Park, J. H.; Lazaryan, A.; Shah, N. N.; Svoboda, J.; Lekakis, L. J.; Reshef, R.; Phillips, C. L.; Burke, L. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of dexamethasone (Dex) dose strength on outcomes in newly diagnosed multiple myeloma (NDMM): A Secondary analysis of SWOG Studies S0777 and S1211
    Meeting Abstract

    Banerjee, R.; Sexton, R.; Cowan, A. J.; Ailawadhi, S.; Rajkumar, S. V.; Kumar, S. K.; Lonial, S.; Barlogie, B.; Durie, B. G. M.; Usmani, S. Z.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The early benefits and psychological effects of screening for monoclonal gammopathy of undetermined significance: Results of the Istopmm study
    Meeting Abstract

    Rögnvaldsson, S.; Thorsteinsdottir, S.; Oskarsson, J.; Eythorsson, E.; Sigurdardottir, G. A.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B.; Sigurdardottir, M.; Olafsson, I.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Early and consistent CRS detection using wearable device for remote patient monitoring following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM): Early results of an investigator-initiated trial
    Meeting Abstract

    Rajeeve, S.; Zahradka, N.; Wilkes, M.; Pan, D.; Calafat, N. J.; Serebryakova, K.; Kappes, K.; Jackson, H.; Buchenholz, N.; Agte, S.; more...
    Blood (2023)

    Fulltext@MSK | Save